Case Study – Motol University Hospital

Challenge

Cardiac disease

Solution

SOPHiA DDM™ Clinical Exome Solution v3

Country

Czech Republic

Motol University Hospital in Prague discover a novel cause of inherited cardiac disease with the SOPHiA DDM™ Clinical Exome Solution v3

Watch Video

The Institute of Biology and Medical Genetics at Motol University Hospital in Prague is a research centre for the analysis of hereditary diseases, part of the largest medical facility in the Czech Republic. The Genetics laboratory has a particular interest in understanding the genetic causes of cardiac diseases.

Research Challenge

The lab received a sample from a man who had experienced a cardiac event that led to cardiopulmonary resuscitation (CPR). To research the underlying genetic cause, the lab initially conducted next-generation sequencing (NGS) with a targeted panel comprised of 100 genes implicated in cardiac disorders. The SOPHiA DDM™ Platform was used to align and call variants from the raw NGS data and subsequently analyze and interpret the results. A potential causative variant was identified, but as a variant of uncertain significance, it required further research.

Confirmation

The lab chose to corroborate their findings using the SOPHiA DDM™ Clinical Exome Solution v3 (CES v3), which enables the analysis of 5000 clinically relevant nuclear and mitochondrial genes, including additional genes implicated in cardiac disease.

Results

The adoption of CES v3 successfully helped to corroborate the pathogenic variant: NM_001256850.1(TTN):c.9358_9610del p.(Arg3120Glufs*58), confirmed by Sanger sequencing. The lab used Alamut™ Visual Plus to visualize the pathogenic variant in the context of the rest of the genome (Figure). First, they highlighted the area of the CNV on the genome viewer and then looked at the gnomAD and ClinVar tracks for similar variants. A variant was absent in healthy controls in gnomAD, therefore, suspected to be causative. The variant had not been previously reported in ClinVar, or the literature and so was considered a novel variant.

Visualization of the pathogenic variant in TTN in Alamut™ Visual Plus.

The detected CNV caused a frameshift and a premature termination codon 58 amino acids downstream, predicted to lead to a truncated or absent titin/connectin protein due to nonsense-mediated mRNA decay. Titin, or connectin, is a giant muscle protein expressed in the cardiac and skeletal muscles. It spans half of the sarcomere and plays a key role in muscle assembly, force transmission, and maintenance of resting tension. Mutations in TTN have previously been associated with cardiomyopathy and muscular dystrophy.

A segregation study found that although the proband’s healthy son lacked the pathogenic variant in TTN, his daughter did possess it and presented with arrhythmogenic right ventricular dysplasia.

Overall, the SOPHiA DDM™ Platform complemented by Alamut™ Visual Plus identified a novel pathogenic variant previously unreported in ClinVar and allowed a segregation study of the proband’s family for the TTN mutation.

“Community Frequency is a very useful tool that enables us to make a quick decision about whether or not to consider a variant and continue with a deeper inspection.”

Motol Hospital, Charles University,
Prague, Czech Republic

Related Case Studies

Case Study: Unlocking access to MSK-ACCESS® for robust liquid biopsy analysis Read More

Genomic Diagnostics, Australia Read More

TomaLab Advanced Biomedical Assays Read More

1 2 3 … 5 Next »

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services